NCT04300309 - Pharmacokinetics, Safety, Tolerability and Efficacy of a New Artemether-lumefantrine Dispersible Tablet in Infants and Neonates <5 kg Body Weight With Acute Uncomplicated Plasmodium Falciparum Malaria | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 21, 2020

Primary Completion Date

July 2, 2023

Study Completion Date

May 10, 2024

Conditions

Plasmodium Falciparum Malaria

Interventions

DRUG

artemether:lumefantrine (2.5 mg:30 mg)

Two oral dispersible tablets twice daily for three consecutive days. Each tablet contained artemether-lumefantrine 2.5 mg:30 mg.

Trial Locations (3)

Novartis Investigative Site, Nanoro

Novartis Investigative Site, Ouagadougou

Novartis Investigative Site, Kisantu